UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

Journal of thrombosis and haemostasis, 2021-10, Vol.19 (10), p.2407-2416

2021

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat

Clinical pharmacokinetics, 2018-06, Vol.57 (6), p.647-661

2018

Volltextzugriff (PDF)

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1)

Chest, 2014-11, Vol.146 (5), p.1274-1285

2014

Volltextzugriff (PDF)

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

Research and practice in thrombosis and haemostasis, 2019-04, Vol.3 (2), p.242-253

2019

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

Journal of clinical pharmacology, 2008-08, Vol.48 (8), p.926-934

2008

Volltextzugriff (PDF)

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S5-S14

2016

Volltextzugriff (PDF)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary circulation, 2019-04, Vol.9 (2), p.1-10

2019

Volltextzugriff (PDF)

Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S15-S26

2016

Volltextzugriff (PDF)

Absorption of Riociguat (BAY 63-2521): Bioavailability, Food Effects, and Dose Proportionality

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S27-S34

2016

Volltextzugriff (PDF)

Bioavailability, Pharmacokinetics, and Safety of Riociguat Given as an Oral Suspension or Crushed Tablet with and without Food

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S66-S74

2016

Volltextzugriff (PDF)

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease

Pulmonary circulation, 2015-06, Vol.5 (2), p.296-304

2015

Volltextzugriff (PDF)

Riociguat (BAY 63-2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S35-S42

2016

Volltextzugriff (PDF)

Pharmacokinetic Interaction of Riociguat with Ketoconazole, Clarithromycin, and Midazolam

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S49-S57

2016

Volltextzugriff (PDF)

Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S97-S102

2016

Volltextzugriff (PDF)

Effects of Omeprazole and Aluminum Hydroxide/Magnesium Hydroxide on Riociguat Absorption

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S43-S48

2016

Volltextzugriff (PDF)

Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study

Chest, 2014-11, Vol.146 (5), p.1274-1285

2014

Volltextzugriff (PDF)

Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian

Clinical pharmacology in drug development, 2023-02, Vol.12 (2), p.219-230

2023

Volltextzugriff (PDF)

Cinaciguat (BAY 58―2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

Circulation (New York, N.Y.), 2009-06, Vol.119 (21), p.2781-2788

2009

Volltextzugriff (PDF)

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

The European respiratory journal, 2021-11, Vol.58 (5), p.2101937

2021

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the α2C‐Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Clinical pharmacology in drug development, 2022-03, Vol.11 (3), p.296-308

2022

Volltextzugriff (PDF)

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Clinical pharmacokinetics, 2016-05, Vol.55 (5), p.615-624

2016

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of the α 2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Clinical pharmacology in drug development, 2022-03, Vol.11 (3), p.296-308

2022

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers

Journal of clinical pharmacology, 2008-12, Vol.48 (12), p.1400-1410

2008

Volltextzugriff (PDF)

Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment

International journal of clinical pharmacology and therapeutics, 2017-03, Vol.55 (3), p.246-255

2017

Volltextzugriff (PDF)

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XI a: First evaluation of safety, pharmacodynamics, and pharmacokinetics

Research and practice in thrombosis and haemostasis, 2019-04, Vol.3 (2), p.242-253

2019

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(46)
Tagungsberichte
(1)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1)

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Absorption of Riociguat (BAY 63-2521): Bioavailability, Food Effects, and Dose Proportionality

Bioavailability, Pharmacokinetics, and Safety of Riociguat Given as an Oral Suspension or Crushed Tablet with and without Food

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease

Riociguat (BAY 63-2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study

Pharmacokinetic Interaction of Riociguat with Ketoconazole, Clarithromycin, and Midazolam

Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women

Effects of Omeprazole and Aluminum Hydroxide/Magnesium Hydroxide on Riociguat Absorption

Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study

Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian

Cinaciguat (BAY 58―2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

Pharmacokinetics, Safety, and Tolerability of the α2C‐Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Pharmacokinetics, Safety, and Tolerability of the α 2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers

Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XI a: First evaluation of safety, pharmacodynamics, and pharmacokinetics

Suchergebnisse filtern